Yarrow Bioscience (YARW) Stock Price

Yarrow Bioscience Price

NYSE·CLOSED
20.30
​
Market closed

Revenue at Yarrow Bioscience has contracted by 1.8% per year over the past 9 years to 570,000.00 USD. For Yarrow Bioscience, the net margin of -4,646.1% is up versus -7,876.4% a few years ago. The consensus 12-month price target for Yarrow Bioscience is 5.75 USD, about 71.7% below where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.

Yarrow Bioscience stock price

Access this data via the Eulerpool API

Yarrow Bioscience business model & stock analysis

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.

Frequently asked questions about Yarrow Bioscience

Analysts currently set an average price target of 5.75 USD for the Yarrow Bioscience stock (median: 5.75 USD), implying -71.7 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the Yarrow Bioscience stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Yarrow Bioscience to generate revenue of 530,181.00 USD and earnings per share of -5,741.94 USD.

Converted at the current exchange rate, the Yarrow Bioscience share trades at 18.12 EUR (20.30 USD).

The expected revenue of Yarrow Bioscience is 530,181.00 USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Yarrow Bioscience is -3.83 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Yarrow Bioscience is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Yarrow Bioscience stock.

The price-to-sales ratio (P/S) of Yarrow Bioscience is currently 25.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Yarrow Bioscience stock.

The Eulerpool Quality Score for Yarrow Bioscience is 2/10.

The ISIN of Yarrow Bioscience is US92941V4077. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Yarrow Bioscience is YARW. The ticker symbol is used to trade Yarrow Bioscience shares on the stock exchange.

Fair ValueTerminal
16.65 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
-
Industry
N/A
Number of shares
Employees
Revenue per Employee
57,000.00 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jan 25, 2018
ISIN
US92941V4077
Market capitalization
872.90 M USDSmall Cap
52-Week Range
PEG
-0.15
P/E ratio
P/Ee 2026
-0.00
P/Ee 2027
-0.00
P/Ee 2028
-0.00
P/Ee 2029
-0.00
P/Ee 2030
-0.00
P/Se
25.52
EV/EBIT
—
P/B Ratio
31.44
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-95.38 %
Dividend
Dividend yield
0.00 %
Est. Dividend Yield
99.01 %
Payout Ratio
0.00 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
1 year+
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
30.00 %
Last updated Oct 11, 2026, 12:25 AM

Yarrow Bioscience Peer Group